Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases

• Conditions: colorectal liver metastases; 10027476

• Registration Number: NL-OMON29757
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Colorectal liver metastases, planned surgical resection within 6 weeks.

Exclusion Criteria

Pregnancy, lactation, recent chemotherapy (within 3 months after last chemotherapy regimen).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Correlation of In-111 labeled bevacizumab and histological VEGF expression.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>